The combination of the Hsp90 inhibitor KW-2478 with the proteasome inhibitor bortezomib showed a stronger inhibition of myeloma (MM) cell growth and synergistic antitumor efficacy in a subcutaneously inoculated human myeloma model [107]. Here, HSP90AB1 is linked to plasma cell myeloma.